Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2022

ASH 2022: Striving to improve treatment options for acute myeloid leukaemia

ASH 2022: Striving to improve treatment options for acute myeloid leukaemia

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and...

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax...

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses...

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in...

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

More from ecancer